Latest News

  • REGULATORY

    9 Apr 2026

    One Injection, One Week: Novo Nordisk Clears a New Bar

  • INNOVATION

    8 Apr 2026

    A Weight-Loss Pill Without the Strings Attached

  • PARTNERSHIPS

    7 Apr 2026

    Insilico Does the Math, Lilly Writes the Check

  • INVESTMENT

    6 Apr 2026

    Meet the Startup Trying to Out-Ozempic Ozempic

The Shot Is So Last Year. Lilly Wants You to Pop a Pill

Lilly scientists working with lab equipment in pharmaceutical research lab

PARTNERSHIPS

31 Mar 2026

Eli Lilly and Nimbus Therapeutics team up in a deal worth up to $1.3B to develop a new oral obesity drug

Wegovy vial and syringe beside a stylized model of metabolic liver and fat cells.

REGULATORY

20 Nov 2025

FDA Nod for Metabolic-Liver Therapy Reshapes Treatment Horizon

FDA expands Wegovy to MASH, potentially expanding the metabolic liver disease market and influencing developer strategy

Red-yellow capsules on a high-tech circuit board symbolizing oral metabolic drug innovation.

PARTNERSHIPS

18 Nov 2025

New Partnership Accelerates Push for Oral Metabolic Breakthroughs

Deep Apple Therapeutics and Novo Nordisk team on a non incretin oral target, stirring new momentum in metabolic research

Novo Nordisk headquarters building symbolizing MASH treatment innovation

INNOVATION

14 Nov 2025

Novo Sparks a New Fight to Fix MASH

Novo’s Akero buy raises the stakes in MASH as investors await key fibrosis data

Close-up illustration of an RNA strand in a biomedical research concept.

INSIGHTS

10 Nov 2025

Lilly’s New RNAi Partner Aims for Two Doses a Year

Eli Lilly and SanegeneBio team up to create long-acting RNAi drugs for obesity and diabetes

Two Victoza liraglutide injection pens displayed on a light wooden surface.

MARKET TRENDS

2 Sep 2025

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

Teva's launch of a Saxenda copy shakes up pricing power, forcing Novo and Lilly to rethink access and affordability.

White Novo Nordisk flags wave on tall poles against a cloudy sky, representing the company’s global presence.

PARTNERSHIPS

29 Aug 2025

Novo Nordisk Bets $550M on RNA's Next Act

Novo Nordisk partners with Replicate Bioscience to develop RNA-based obesity therapies, aiming to evolve beyond current GLP-1 blockbusters...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.